Title
A Phase 1b Study of PPI-461 in Patients With HCV Genotype 1
A Phase 1b Study to Assess the Safety, Antiviral Efficacy and Pharmacokinetics of PPI-461 in Patients With HCV Genotype-1 Infection
Phase
Phase 1Lead Sponsor
Presidio PharmaceuticalsStudy Type
InterventionalStatus
Completed No Results PostedIndication/Condition
Chronic Genotype 1 Hepatitis C Virus InfectionIntervention/Treatment
ppi-461 ...Study Participants
24The purpose of the study is to assess the safety, tolerability, antiviral effects, and pharmacokinetics of PPI-461 in patients with chronic hepatitis C virus genotype 1 infection.
capsule, oral, once daily for 3 days
capsules, oral, once daily for 3 days
Eligibility Criteria: Male or female, between 18 and 65 years of age (female patients must be surgically sterile or 2 years post-menopausal and are required to take a pregnancy test) Body Mass Index (BMI) 18 - 32 kg/m2 Chronically infected with hepatitis C genotype-1 virus Serum HCV RNA > 5 log10 IU/mL No previous treatment with interferon, peginterferon, ribavirin or any investigational HCV antiviral agents No history of signs or symptoms of decompensated liver disease No known history of cirrhosis No co-infection with HBV, HIV-1, HIV-2 No history of any medical condition that may interfere with absorption, distribution or elimination of study drug or with the clinical and laboratory assessments in this study No history of alcohol abuse, or illicit drug use within 2 years prior to Screen, or enrollment in a methadone maintenance program (unless he/she has been enrolled in the methadone program for at least 3 months with good compliance, stable psychosocial circumstances, and no known current risks for recidivism)